Showing 1611-1620 of 1692 results for "".
- Deadline Approaching for Grant Submissions to American Epilepsy Society for Fundinghttps://practicalneurology.com/news/deadline-approaching-for-grant-submissions-to-american-epilepsy-society-for-funding/2470431/The American Epilepsy Society (AES) has funding opportunities for established investigators who conduct basic, translational, and clinical research in seizures, epilepsy, and related disorders. The AES encourages applicants to submit proposals by the forthcoming deadline of April 3, 2024. <
- Real-World Study Results Demonstrate Efficacy of Kesimpta Treatment for Reducing Relapse Rates in Multiple Sclerosis Patientshttps://practicalneurology.com/news/real-world-study-results-demonstrate-efficacy-of-kesimpta-treatment-for-reducing-relapse-rates-in-multiple-sclerosis-patients/2470412/Study results presented at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 demonstrated the efficacy of Kesimpta (ofatumumab; Novartis, East Hanover, NJ) treatment for reducing incidence of relapses in a real world sample of multiple scler
- Novel Brain Cytoprotection Combination Therapy Associated with Improved Functional Outcomes in People with Acute Ischemic Strokehttps://practicalneurology.com/news/novel-brain-cytoprotection-combination-therapy-associated-with-improved-functional-outcomes-in-people-with-acute-ischemic-stroke/2470408/The use of Sanbexin (edaravone and dexborneol; Simcere, Nanjing, China) sublingual tablets, a formulation combining edaravone and dexborneol, was found to result in statistically significant improvements in functional outcomes for people with acute ischemic stroke (AIS) compared with placebo. The
- FDA Grants 510(k) Clearance to Thin-Film SEEG-Guided Radiofrequency Ablation System for Neurosurgeryhttps://practicalneurology.com/news/fda-grants-510k-clearance-to-thin-film-seeg-guided-radiofrequency-ablation-system-for-neurosurgery/2470363/The Food and Drug Administration (FDA) has granted 510(k) clearance to the OneRF Ablation System (NeuroOne, Eden Prairie, MN), according to an announcement from NeuroOne. The OneRF Ablation System produces radiofrequencies that generate heat to ablate nervous tissue for use in neurosurgery, with
- Subcutaneous Ocrevus Similar to IV Treatment for Patients with PPMS or RMShttps://practicalneurology.com/news/subcutaneous-ocrevus-similar-to-iv-treatment-for-patients-with-ppms-or-rms/2470252/Subcutaneous injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) was comparable to the intravenous (IV) infusion formulation of Ocrevus in treating patients with primary progressive multiple sclerosis (PP
- Foslevodopa/Foscarbidopa Treatment for Advanced Parkinson Disease Associated with Significant Quality of Life Improvements According to Interim Analysis of Clinical Trial Datahttps://practicalneurology.com/news/foslevodopafoscarbidopa-treatment-for-advanced-parkinson-disease-associated-with-significant-quality-of-life-improvements-according-to-interim-analysis-of-clinical-trial-data/2470237/Patients with advanced Parkinson disease (aPD) treated with foslevodopa/foscarbidopa (ABBV-951, AbbVie; North Chicago, IL), a soluble formulation of levodopa/carbidopa prodrugs delivered as a 24-hour/day continuous subcutan
- Approval and Orphan Drug Exclusivity Granted by FDA For Sodium Oxybate to Treat Cataplexyhttps://practicalneurology.com/news/approval-and-orphan-drug-exclusivity-granted-by-fda-for-sodium-oxybate-to-treat-cataplexy/2470174/The Food and Drug Administration (FDA) has granted approval for an extended-release formulation of the central nervous system depressant sodium oxybate (Lumryz; Avadel Pharmaceuticals, Dublin, Ireland) to treat cataplexy or
- Antidepressants Safe in Those Taking Ozanimod for Relapsing MShttps://practicalneurology.com/news/antidepressants-safe-in-those-taking-ozanimod-for-relapsing-ms/2470123/Data presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) Forum 2023 suggest that concurrent administration of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) with selectiv
- Phase 3 Trial of New Drug To Treat Progressive MS Approved by FDAhttps://practicalneurology.com/news/phase-3-trial-of-new-drug-to-treat-progressive-ms-cleared-by-fda/2470089/The Food and Drug Administration (FDA) approved a phase 3 clinical trial (NCT05441488) for masitinib (AB Science; Paris, France) as a potential treatment for progressive forms of multiple sclerosi
- FDA Approves Monoclonal Antibody for Treating Relapsing MShttps://practicalneurology.com/news/fda-approves-monoclonal-antibody-for-treating-relapsing-ms/2470088/The Food and Drug Administration (FDA) approved ublituximab (Briumvi; TG Therapeutics, New York, NY) for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.